<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55001805"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>

	<byline>
	<affiliation>European Medicines Agency<lb/> Evaluation of Medicines for Human Use<lb/></affiliation>
	</byline>

	<address>7 Westferry Circus, Canary Wharf, London, E14 4HB, UK<lb/></address>

	<phone>Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 85 45<lb/></phone>

	<email>E-mail: mail@emea.europa.eu</email>

	<ptr type="web">http://www.emea.europa.eu<lb/></ptr>

	<docTitle>
	<titlePart>ASSESSMENT REPORT<lb/> FOR<lb/> AREPANRIX<lb/> </titlePart>
	</docTitle>
	
	<note type="other">Common Name:<lb/> Pandemic Influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)<lb/> A/California/7/2009 (H1N1)v like strain (X-179A)<lb/></note>
	
	<idno> Procedure No. EMEA/H/C/001201<lb/> </idno>
	
	<note type="other">Assessment Report as adopted by the CHMP with<lb/> all information of a commercially confidential nature deleted.</note>

		</front>
	</text>
</tei>
